Evidence map›Paper›PMID 32933049›Full record

ReviewInternational journal of molecular sciences2020

MuRF1/TRIM63, Master Regulator of Muscle Mass.

Dulce Peris-Moreno, Daniel Taillandier, Cécile Polge

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 2 syntheses or guidelines pooled it, 134 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Novel biomarkers for sarcopenia: a narrative review.Journal of orthopaedic surgery and research · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Nutrients · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Attrition of amino acids in the life span of broiler chickens.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2025
    Review

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Dulce Peris-MorenoINRA, UNH, Unité de Nutrition Humaine, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.ORCID 0000-0001-6818-5900
Daniel TaillandierINRA, UNH, Unité de Nutrition Humaine, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.
Cécile PolgeINRA, UNH, Unité de Nutrition Humaine, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.ORCID 0000-0002-8730-5776
Université Clermont Auvergne · FR

Funding

AFM-Téléthon #19521Fondation pour la Recherche Médicale DEQ20180339180H2020 Marie Skłodowska-Curie Actions GA 813599IDEX-ISITE initiative (CAP 20e25) 16-IDEX-0001
6 · The paper itself

Abstract

The E3 ubiquitin ligase MuRF1/TRIM63 was identified 20 years ago and suspected to play important roles during skeletal muscle atrophy. Since then, numerous studies have been conducted to decipher the roles, molecular mechanisms and regulation of this enzyme. This revealed that MuRF1 is an important player in the skeletal muscle atrophy process occurring during catabolic states, making MuRF1 a prime candidate for pharmacological treatments against muscle wasting. Indeed, muscle wasting is an associated event of several diseases (e.g., cancer, sepsis, diabetes, renal failure, etc.) and negatively impacts the prognosis of patients, which has stimulated the search for MuRF1 inhibitory molecules. However, studies on MuRF1 cardiac functions revealed that MuRF1 is also cardioprotective, revealing a yin and yang role of MuRF1, being detrimental in skeletal muscle and beneficial in the heart. This review discusses data obtained on MuRF1, both in skeletal and cardiac muscles, over the past 20 years, regarding the structure, the regulation, the location and the different functions identified, and the first inhibitors reported, and aim to draw the picture of what is known about MuRF1. The review also discusses important MuRF1 characteristics to consider for the design of future drugs to maintain skeletal muscle mass in patients with different pathologies.

Indexed as

AnimalsHumansMuscle ProteinsMuscle, SkeletalMuscular AtrophyMyocardiumUbiquitin-Protein LigasesMuscle ProteinsUbiquitin-Protein Ligasesatrophycardiomyopathychronic diseasescontractile proteinshearthypertrophyMuRF1/TRIM63pharmacological inhibitorsskeletal muscleTRIM E3 ligase

Identifiers

PMID32933049
PMCPMC7555135
OpenAlexW3086251256

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.